Myeloma NZ

Multiple myeloma (MM) is the second most common hematologic malignancy and represents approximately 10% of all hematological neoplasms. Standard...

Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients...

The addition of elotuzumab (Empliciti) to pomalidomide (Pomalyst) and dexamethasone cut the risk of disease progression or death by 46% compared...

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results...

Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients...

CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a...

CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before...

When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine...

CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Dr Rob Weinkove spoke at our patient seminar on CAR T-Cell Therapy: a New Frontier in...